Merck (MRK) Stock Forecast, Price Target & Predictions
MRK Stock Forecast
Merck stock forecast is as follows: an average price target of $129.47 (represents a 27.09% upside from MRK’s last price of $101.87) and a rating consensus of 'Buy', based on 23 wall street analysts offering a 1-year stock forecast.
MRK Price Target
The average price target for Merck (MRK) is $129.47 based on 1-year price targets from 23 Wall Street analysts in the past 3 months, with a price target range of $294.00 to $80.00. This represents a potential 27.09% upside from MRK's last price of $101.87.
MRK Analyst Ratings
According to 23 Wall Street analysts, Merck's rating consensus is 'Buy'. The analyst rating breakdown for MRK stock is 0 'Strong Buy' (0.00%), 21 'Buy' (91.30%), 2 'Hold' (8.70%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Merck Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 09, 2024 | Trung Huynh | UBS | $136.00 | $108.88 | 24.91% | 33.50% |
| Oct 07, 2024 | Carter Gould | Barclays | $140.00 | $109.77 | 27.54% | 37.43% |
| Aug 15, 2024 | Akash Tewari | Jefferies | $147.00 | $113.49 | 29.53% | 44.30% |
| Jul 31, 2024 | Colin Bristow | UBS | $142.00 | $112.89 | 25.79% | 39.39% |
| Jul 31, 2024 | Geoff Meacham | Bank of America Securities | $145.00 | $115.21 | 25.86% | 42.34% |
| Jun 12, 2024 | Mohit Bansal | Wells Fargo | $140.00 | $131.05 | 6.83% | 37.43% |
| May 30, 2024 | Evan David Seigerman | BMO Capital | $148.00 | $127.71 | 15.89% | 45.28% |
| Mar 27, 2024 | - | Truist Financial | $142.00 | $130.81 | 8.55% | 39.39% |
| Mar 27, 2024 | Akash Tewari | Jefferies | $145.00 | $130.18 | 11.38% | 42.34% |
| Mar 27, 2024 | Mohit Bansal | Wells Fargo | $135.00 | $130.19 | 3.69% | 32.52% |
The latest Merck stock forecast, released on Oct 09, 2024 by Trung Huynh from UBS, set a price target of $136.00, which represents a 24.91% increase from the stock price at the time of the forecast ($108.88), and a 33.50% increase from MRK last price ($101.87).
Merck Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 11 |
| Avg Price Target | $138.00 | $141.00 | $141.09 |
| Last Closing Price | $101.87 | $101.87 | $101.87 |
| Upside/Downside | 35.47% | 38.41% | 38.50% |
In the current month, the average price target of Merck stock is $138.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 35.47% increase as opposed to Merck's last price of $101.87. This month's average price target is down -2.13% compared to last quarter, and down -2.19% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 17, 2024 | Bernstein | - | Market Perform | Initialise |
| Oct 09, 2024 | UBS | Buy | Buy | Hold |
| Oct 07, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 16, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 16, 2024 | UBS | Underperform | Underperform | Hold |
| Sep 13, 2024 | Needham | Hold | Hold | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 15, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 05, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jul 31, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
Merck's last stock rating was published by Bernstein on Oct 17, 2024. The company Initialise its MRK rating from "null" to "Market Perform".
Merck Financial Forecast
Merck Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $15.96B | $15.04B | $14.49B | $13.83B | $14.96B | $14.59B | $15.90B | $13.52B | $13.15B | $11.40B | $12.08B | $12.52B | $12.55B | $10.87B | $12.06B | $11.87B | $12.40B | $11.76B | $10.82B | $10.04B | $9.43B |
| Avg Forecast | $16.73B | $16.75B | $16.80B | $16.28B | $15.59B | $16.47B | $15.87B | $15.21B | $14.49B | $15.30B | $14.44B | $13.79B | $13.66B | $14.07B | $13.86B | $14.56B | $13.16B | $12.32B | $11.23B | $12.61B | $12.67B | $12.21B | $10.40B | $11.48B | $11.98B | $11.64B | $10.96B | $10.47B | $9.56B | $8.90B |
| High Forecast | $17.02B | $17.04B | $17.09B | $16.56B | $15.80B | $16.50B | $15.87B | $15.21B | $14.88B | $15.57B | $14.69B | $14.03B | $13.90B | $14.07B | $13.86B | $14.56B | $13.16B | $12.32B | $11.23B | $12.61B | $12.67B | $12.21B | $10.40B | $11.48B | $11.98B | $11.64B | $10.96B | $10.47B | $11.47B | $10.68B |
| Low Forecast | $16.41B | $16.43B | $16.48B | $15.97B | $15.25B | $16.44B | $15.87B | $15.21B | $14.26B | $14.60B | $14.17B | $13.53B | $13.40B | $14.07B | $13.86B | $14.56B | $13.16B | $12.32B | $11.23B | $12.61B | $12.67B | $12.21B | $10.40B | $11.48B | $11.98B | $11.64B | $10.96B | $10.47B | $7.65B | $7.12B |
| # Analysts | 1 | 1 | 1 | 1 | 10 | 9 | 3 | 4 | 7 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.04% | 1.04% | 1.05% | 1.01% | 1.06% | 1.05% | 1.09% | 1.03% | 1.07% | 1.02% | 0.96% | 0.99% | 1.03% | 1.05% | 1.05% | 0.99% | 1.07% | 1.07% | 1.03% | 1.05% | 1.06% |
Merck's average Quarter revenue forecast for Dec 23 based on 7 analysts is $14.49B, with a low forecast of $14.26B, and a high forecast of $14.88B. MRK's average Quarter revenue forecast represents a -9.23% decrease compared to the company's last Quarter revenue of $15.96B (Sep 23).
Merck EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 10 | 9 | 3 | 4 | 7 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | $6.00B | $-4.86B | $3.87B | $3.54B | $4.20B | $5.21B | $5.67B | $4.89B | $6.22B | $2.94B | $4.58B | $-885.00M | $4.48B | $4.77B | $4.87B | $3.94B | $3.42B | $4.49B | $4.23B | $2.66B | $3.37B |
| Avg Forecast | $4.59B | $4.59B | $4.61B | $4.46B | $4.28B | $4.52B | $4.35B | $6.26B | $3.97B | $4.19B | $3.96B | $5.69B | $4.43B | $3.86B | $3.80B | $5.17B | $3.61B | $3.38B | $3.08B | $5.23B | $3.47B | $3.35B | $2.85B | $4.29B | $3.28B | $3.19B | $3.00B | $3.59B | $2.53B | $3.17B |
| High Forecast | $4.67B | $4.67B | $4.69B | $4.54B | $4.33B | $4.53B | $4.35B | $7.51B | $4.08B | $4.27B | $4.03B | $6.83B | $5.31B | $3.86B | $3.80B | $6.21B | $3.61B | $3.38B | $3.08B | $6.28B | $3.47B | $3.35B | $2.85B | $5.15B | $3.28B | $3.19B | $3.00B | $4.31B | $3.03B | $3.80B |
| Low Forecast | $4.50B | $4.51B | $4.52B | $4.38B | $4.18B | $4.51B | $4.35B | $5.01B | $3.91B | $4.00B | $3.89B | $4.55B | $3.54B | $3.86B | $3.80B | $4.14B | $3.61B | $3.38B | $3.08B | $4.19B | $3.47B | $3.35B | $2.85B | $3.43B | $3.28B | $3.19B | $3.00B | $2.87B | $2.02B | $2.54B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.43% | -1.23% | 0.68% | 0.80% | 1.09% | 1.37% | 1.10% | 1.35% | 1.84% | 0.95% | 0.88% | -0.25% | 1.34% | 1.67% | 1.14% | 1.20% | 1.07% | 1.49% | 1.18% | 1.05% | 1.06% |
7 analysts predict MRK's average Quarter EBITDA for Dec 23 to be $3.97B, with a high of $4.08B and a low of $3.91B. This is -33.76% lower than Merck's previous annual EBITDA (Sep 23) of $6.00B.
Merck Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 10 | 9 | 3 | 4 | 7 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | $4.75B | $-5.97B | $2.82B | $3.02B | $3.25B | $3.94B | $4.31B | $3.82B | $4.57B | $1.54B | $3.18B | $-2.09B | $2.94B | $3.00B | $3.22B | $2.36B | $1.90B | $2.67B | $2.92B | $736.00M | $1.55B |
| Avg Forecast | $5.54B | $6.52B | $6.16B | $5.78B | $4.75B | $3.77B | $5.51B | $4.33B | $-275.62M | $4.96B | $-5.54B | $3.94B | $3.40B | $4.34B | $4.33B | $3.58B | $3.88B | $3.93B | $3.33B | $3.63B | $3.36B | $3.49B | $2.57B | $2.83B | $2.79B | $3.01B | $2.81B | $2.48B | $699.20M | $1.46B |
| High Forecast | $5.67B | $6.67B | $6.30B | $5.91B | $4.85B | $3.84B | $5.51B | $5.20B | $-61.25M | $5.29B | $-5.40B | $4.73B | $4.09B | $4.34B | $4.33B | $4.30B | $3.88B | $3.93B | $3.33B | $4.35B | $3.36B | $3.49B | $2.57B | $3.40B | $2.79B | $3.01B | $2.81B | $2.97B | $839.04M | $1.75B |
| Low Forecast | $5.41B | $6.36B | $6.01B | $5.64B | $4.60B | $3.70B | $5.50B | $3.47B | $-428.74M | $4.56B | $-5.67B | $3.15B | $2.72B | $4.34B | $4.33B | $2.86B | $3.88B | $3.93B | $3.33B | $2.90B | $3.36B | $3.49B | $2.57B | $2.27B | $2.79B | $3.01B | $2.81B | $1.98B | $559.36M | $1.17B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.96% | 1.08% | 0.72% | 0.89% | 0.75% | 0.91% | 1.20% | 0.98% | 1.16% | 0.46% | 0.88% | -0.62% | 0.84% | 1.17% | 1.14% | 0.85% | 0.63% | 0.95% | 1.18% | 1.05% | 1.06% |
Merck's average Quarter net income forecast for Dec 23 is $-275.62M, with a range of $-428.74M to $-61.25M. MRK's average Quarter net income forecast represents a -105.81% decrease compared to the company's last Quarter net income of $4.75B (Sep 23).
Merck SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 10 | 9 | 3 | 4 | 7 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | $2.52B | $2.70B | $2.48B | $2.69B | $2.52B | $2.51B | $2.32B | $2.83B | $2.34B | $2.28B | $2.63B | $3.08B | $2.45B | $2.38B | $2.56B | $2.89B | $2.59B | $2.71B | $2.42B | $2.51B | $2.41B |
| Avg Forecast | $3.29B | $3.30B | $3.31B | $3.20B | $3.07B | $3.24B | $3.12B | $2.33B | $2.85B | $3.01B | $2.84B | $2.12B | $2.56B | $2.77B | $2.73B | $1.93B | $2.59B | $2.42B | $2.21B | $3.00B | $2.49B | $2.40B | $2.05B | $2.25B | $2.36B | $2.29B | $2.16B | $2.06B | $2.38B | $2.27B |
| High Forecast | $3.35B | $3.35B | $3.37B | $3.26B | $3.11B | $3.25B | $3.12B | $2.80B | $2.93B | $3.06B | $2.89B | $2.55B | $3.08B | $2.77B | $2.73B | $2.32B | $2.59B | $2.42B | $2.21B | $3.61B | $2.49B | $2.40B | $2.05B | $2.70B | $2.36B | $2.29B | $2.16B | $2.47B | $2.86B | $2.72B |
| Low Forecast | $3.23B | $3.23B | $3.24B | $3.14B | $3.00B | $3.24B | $3.12B | $1.87B | $2.81B | $2.87B | $2.79B | $1.70B | $2.05B | $2.77B | $2.73B | $1.54B | $2.59B | $2.42B | $2.21B | $2.40B | $2.49B | $2.40B | $2.05B | $1.80B | $2.36B | $2.29B | $2.16B | $1.65B | $1.91B | $1.81B |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.84% | 0.95% | 1.17% | 1.05% | 0.91% | 0.92% | 1.20% | 1.09% | 0.96% | 1.03% | 0.88% | 1.24% | 1.02% | 1.16% | 1.14% | 1.23% | 1.13% | 1.26% | 1.18% | 1.05% | 1.06% |
Merck's average Quarter SG&A projection for Dec 23 is $2.85B, based on 7 Wall Street analysts, with a range of $2.81B to $2.93B. The forecast indicates a 13.22% rise compared to MRK last annual SG&A of $2.52B (Sep 23).
Merck EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 10 | 9 | 3 | 4 | 7 | 15 | 9 | 9 | 13 | 13 | 13 | 13 | 7 | 7 | 7 | 7 | 9 | 16 | 8 | 11 | 7 | 11 | 7 | 7 | 17 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | $1.87 | $-2.35 | $1.11 | $1.19 | $1.28 | $1.56 | $1.70 | $1.51 | $1.81 | $0.61 | $1.26 | $-0.83 | $1.16 | $1.19 | $1.28 | $0.93 | $0.75 | $1.04 | $1.13 | $0.27 | $0.57 |
| Avg Forecast | $2.18 | $2.56 | $2.43 | $2.28 | $1.87 | $1.48 | $2.17 | $1.89 | $-0.11 | $1.95 | $-2.18 | $1.32 | $1.53 | $1.71 | $1.70 | $1.83 | $1.53 | $1.55 | $1.31 | $1.53 | $1.32 | $1.37 | $1.01 | $1.28 | $1.10 | $1.18 | $1.10 | $1.00 | $0.95 | $0.78 |
| High Forecast | $2.23 | $2.62 | $2.48 | $2.33 | $1.91 | $1.51 | $2.17 | $1.89 | $-0.02 | $2.08 | $-2.13 | $1.38 | $1.57 | $1.71 | $1.70 | $1.83 | $1.53 | $1.55 | $1.31 | $1.53 | $1.32 | $1.37 | $1.01 | $1.28 | $1.10 | $1.18 | $1.10 | $1.00 | $1.14 | $0.94 |
| Low Forecast | $2.13 | $2.50 | $2.37 | $2.22 | $1.81 | $1.46 | $2.17 | $1.88 | $-0.17 | $1.79 | $-2.23 | $1.27 | $1.50 | $1.71 | $1.70 | $1.83 | $1.53 | $1.55 | $1.31 | $1.53 | $1.32 | $1.37 | $1.01 | $1.28 | $1.10 | $1.18 | $1.10 | $1.00 | $0.76 | $0.62 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.96% | 1.08% | 0.84% | 0.78% | 0.75% | 0.92% | 0.93% | 0.99% | 1.17% | 0.47% | 0.82% | -0.63% | 0.85% | 1.18% | 1.00% | 0.85% | 0.63% | 0.94% | 1.13% | 0.28% | 0.73% |
According to 7 Wall Street analysts, Merck's projected average Quarter EPS for Dec 23 is $-0.11, with a low estimate of $-0.17 and a high estimate of $-0.02. This represents a -105.80% decrease compared to MRK previous annual EPS of $1.87 (Sep 23).
Merck Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $27.76 | $44.76 | 61.24% | Hold |
| MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
| BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
| JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
| LLY | Eli Lilly and Company | $806.14 | $782.65 | -2.91% | Buy |
| AMGN | Amgen | $316.91 | $293.15 | -7.50% | Buy |
| GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
| ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
MRK Forecast FAQ
Is Merck a good buy?
Yes, according to 23 Wall Street analysts, Merck (MRK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 21 'Buy' recommendations, accounting for 91.30% of MRK's total ratings.
What is MRK's price target?
Merck (MRK) average price target is $129.47 with a range of $80 to $294, implying a 27.09% from its last price of $101.87. The data is based on 23 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Merck stock go up soon?
According to Wall Street analysts' prediction for MRK stock, the company can go up by 27.09% (from the last price of $101.87 to the average price target of $129.47), up by 188.60% based on the highest stock price target, and down by -21.47% based on the lowest stock price target.
Can Merck stock reach $200?
MRK's highest twelve months analyst stock price target of $294 supports the claim that Merck can reach $200 in the near future.
What is Merck's current price target trend?
2 Wall Street analysts forecast a $138 price target for Merck (MRK) this month, up 35.47% from its last price of $101.87. Compared to the last 3 and 12 months, the average price target increased by 38.41% and increased by 38.50%, respectively.
What are Merck's analysts' financial forecasts?
Merck's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $63.14B (high $63.38B, low $62.76B), average EBITDA is $19.4B (high $20.72B, low $18.05B), average net income is $18.36B (high $19.4B, low $17.26B), average SG&A $11.77B (high $12.28B, low $11.23B), and average EPS is $7.41 (high $7.48, low $7.31). MRK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $66.56B (high $67.72B, low $65.3B), average EBITDA is $18.25B (high $18.57B, low $17.91B), average net income is $24B (high $24.55B, low $23.41B), average SG&A $13.1B (high $13.33B, low $12.85B), and average EPS is $9.45 (high $9.66, low $9.21).
Did the MRK's actual financial results beat the analysts' financial forecasts?
Based on Merck's last annual report (Dec 2022), the company's revenue was $59.28B, beating the average analysts forecast of $56.13B by 5.61%. Apple's EBITDA was $18.62B, beating the average prediction of $17.26B by 7.90%. The company's net income was $14.52B, missing the average estimation of $15.66B by -7.27%. Apple's SG&A was $10.04B, beating the average forecast of $9.99B by 0.53%. Lastly, the company's EPS was $5.73, missing the average prediction of $6.77 by -15.36%. In terms of the last quarterly report (Sep 2023), Merck's revenue was $15.96B, beating the average analysts' forecast of $15.3B by 4.35%. The company's EBITDA was $6B, beating the average prediction of $4.19B by 42.99%. Merck's net income was $4.74B, missing the average estimation of $4.96B by -4.40%. The company's SG&A was $2.52B, missing the average forecast of $3.01B by -16.34%. Lastly, the company's EPS was $1.87, missing the average prediction of $1.95 by -4.27%